drugset

drugset / Trial / NCT07303790

This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

NCT07303790 ↗

Phase 0 Recruiting 9 enrolled Daishi Tian

NaSingle-groupOpen-labelTreatment

Summary

This is an early exploratory study to assess the tolerability and safety of GC012F CAR T cell injection in Multiple Sclerosis patients.

Timeline

Start: 2026-03-09
Primary completion: 2027-01-20
Completion: 2028-12-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GC012F	Cell therapy	—	Intravenous

Indications